Article
Oncology
Dae-Hwan Kim, Duanchen Sun, William K. Storck, Katherine Welker Leng, Chelsea Jenkins, Daniel J. Coleman, David Sampson, Xiangnan Guan, Anbarasu Kumaraswamy, Eva S. Rodansky, Joshua A. Urrutia, Jacob A. Schwartzman, Chao Zhang, Himisha Beltran, Mark P. Labrecque, Colm Morrissey, Jared M. Lucas, Ilsa M. Coleman, Peter S. Nelson, Eva Corey, Samuel K. Handelman, Jonathan Z. Sexton, Rahul Aggarwal, Wassim Abida, Felix Y. Feng, Eric J. Small, Daniel E. Spratt, Armand Bankhead, Arvind Rao, Emily M. Gesner, Sarah Attwell, Sanjay Lakhotia, Eric Campeau, Joel A. Yates, Zheng Xia, Joshi J. Alumkal
Summary: NEPC is the most aggressive lineage plasticity in prostate cancer, with limited treatment options. By inhibiting AR and using BET inhibitors, it is possible to block this lineage plasticity, showing promising potential for t-NEPC treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Eunjeong Seo, Byula Jee, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Minyong Kang
Summary: In this study, the researchers discovered that the AR-V7/YAP1/TAZ axis represses the expression of SLC22A3, leading to resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). This finding provides new insights into potential treatment targets for prostate cancer.
Article
Cell Biology
Boya Zhang, Mingpeng Zhang, Chunyi Shen, Guancong Liu, Fan Zhang, Jingyu Hou, Weitao Yao
Summary: The study revealed the key role of LncRNA PCBP1-AS1 in drug resistance of castration-resistant prostate cancer, by stabilizing the AR/AR-V7 complex to prevent degradation. Targeting PCBP1-AS1 can significantly restore drug sensitivity in resistant tumors.
CELL DEATH & DISEASE
(2021)
Review
Oncology
Zeyuan Zheng, Jinxin Li, Yankuo Liu, Zhiyuan Shi, Zuodong Xuan, Kunao Yang, Chunlan Xu, Yang Bai, Meiling Fu, Qiaohong Xiao, Huimin Sun, Chen Shao
Summary: This review summarizes the mechanisms and biological behaviors of AR-V7 in enzalutamide resistance of castration-resistant prostate cancer (CRPC), providing novel insights for CRPC therapy.
Article
Oncology
Lin Gao, Wenbo Zhang, Jing Zhang, Junmei Liu, Feifei Sun, Hui Liu, Jing Hu, Xin Wang, Xueli Wang, Peng Su, Shouzhen Chen, Sifeng Qu, Benkang Shi, Xueting Xiong, Weiwen Chen, Xuesen Dong, Bo Han
Summary: The study reveals that KIF15 contributes to enzalutamide resistance by enhancing AR signaling, and suggests that cotargeting KIF15 and AR may be an effective therapeutic strategy for prostate cancer.
Article
Chemistry, Physical
Abu Baker, Asad Syed, Sana Iram, Abdallah M. Elgorban, Helal F. Al-Harthi, Salim S. Al-Rejaie, Jihoe Kim, Mohd Sajid Khan
Summary: This study investigates the delivery of enzalutamide (enza) to AR-null cells via EnSvGNPs, which showed anticancer potential and synergistic effects with enza. The study confirms the synthesis and characterizations of EnSvGNPs and SvGNPs, and demonstrates the safe and effective inhibition of cancer cell growth. This targeted delivery system has significant implications for the treatment of metastatic castrate resistance prostate cancer.
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
(2022)
Article
Multidisciplinary Sciences
Xintao Qiu, Nadia Boufaied, Tarek Hallal, Avery Feit, Anna de Polo, Adrienne M. Luoma, Walaa Alahmadi, Janie Larocque, Giorgia Zadra, Yingtian Xie, Shengqing Gu, Qin Tang, Yi Zhang, Sudeepa Syamala, Ji-Heui Seo, Connor Bell, Edward O'Connor, Yang Liu, Edward M. Schaeffer, R. Jeffrey Karnes, Sheila Weinmann, Elai Davicioni, Colm Morrissey, Paloma Cejas, Leigh Ellis, Massimo Loda, Kai W. Wucherpfennig, Mark M. Pomerantz, Daniel E. Spratt, Eva Corey, Matthew L. Freedman, X. Shirley Liu, Myles Brown, Henry W. Long, David P. Labbe
Summary: c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression. MYC overexpression diminishes the androgen receptor (AR) transcriptional program, contributing to prostate tumor initiation and progression.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Jacob J. Orme, Lance C. Pagliaro, J. Fernando Quevedo, Sean S. Park, Brian A. Costello
Summary: This report provides a comprehensive overview of the evidence and rational sequencing strategies for the use of second-generation antiandrogens in prostate cancer treatment. It highlights the growing list of approvals and indications for these drugs and suggests a prioritization sequence for their use in different stages of the disease. The report concludes that an optimized sequencing of second-generation antiandrogens with other treatment options is feasible based on current data.
Article
Biochemistry & Molecular Biology
Andre Richters, Shelby K. Doyle, David B. Freeman, Christina Lee, Becky S. Leifer, Sajjeev Jagannathan, Florian Kabinger, Jost Vrabic Koren, Nicholas B. Struntz, Julie Urgiles, Ryan A. Stagg, Brice H. Curtin, Deep Chatterjee, Sebastian Mathea, Peter J. Mikochik, Tamara D. Hopkins, Hua Gao, Jonathan R. Branch, Hong Xin, Lori Westover, Gilles C. Bignan, Brent A. Rupnow, Kristen L. Karlin, Calla M. Olson, Thomas F. Westbrook, Joseph Vacca, Chris M. Wilfong, B. Wesley Trotter, Douglas C. Saffran, Norbert Bischofberger, Stefan Knapp, Joshua W. Russo, Ian Hickson, James R. Bischoff, Marco M. Gottardis, Steven P. Balk, Charles Y. Lin, Marius S. Pop, Angela N. Koehler
Summary: By targeting CDK9, the inhibitors KI-ARv-03 and KB-0742 show potent anti-tumor activity in CRPC models, reducing transcription and proliferation in prostate cancer cells. These findings suggest CDK9 inhibition as a promising therapeutic strategy for targeting AR dependence in CRPC.
CELL CHEMICAL BIOLOGY
(2021)
Article
Cell Biology
Tingting Zhou, Shengli Wang, Xiaoyu Song, Wensu Liu, Fang Dong, Yunlong Huo, Renlong Zou, Chunyu Wang, Siyi Zhang, Wei Liu, Ge Sun, Lin Lin, Kai Zeng, Xiang Dong, Qiqiang Guo, Fei Yi, Zhuo Wang, Xiaoman Li, Bo Jiang, Liu Cao, Yue Zhao
Summary: The study reveals the potential function of RNF8 in prostate cancer progression and its correlation with poor prognosis. RNF8 regulates prostate cancer development by altering histone modifications and promoting AR transcriptional activity and recruitment. RNF8 may serve as a potential therapeutic target for endocrine-resistant prostate cancer.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Marvin C. J. Lim, Anne-Marie Baird, John Greene, Ciara McNevin, Karine Ronan, Petar Podlesniy, Orla Sheils, Steven G. Gray, Ray S. McDermott, Stephen P. Finn
Summary: This study evaluated the role of circRNAs in enzalutamide-resistant prostate cancer, identifying hsa_circ_0001275 as a potential therapeutic target. The research also explored the trend of circRNA expression in patient plasma, showing a possible association with enzalutamide resistance.
Article
Oncology
Jing Wei, Lijuan Yin, Jingjing Li, Jing Wang, Tianjie Pu, Peng Duan, Tzu-Ping Lin, Allen C. Gao, Boyang Jason Wu
Summary: The study reveals a reciprocal regulatory circuit between MAOA and AR in prostate cancer, with implications for cancer development and growth, particularly CRPC. Targeting MAOA may enhance the efficacy of AR-targeted therapies.
Review
Oncology
Wout Devlies, Florian Handle, Gaetan Devos, Steven Joniau, Frank Claessens
Summary: This review investigates the existing methods to study treatment resistance to androgen receptor targeted therapies in prostate cancer, including the role of preclinical models and understanding of resistance mechanisms. Understanding resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.
Article
Medicine, Research & Experimental
Jianzhong Ai, Jia Li, Qin Su, Hong Ma, Qiang Wei, Hong Li, Guangping Gao
Summary: This study found that PTEN and CDKN1B expression levels were significantly downregulated in prostate cancer cells, suggesting that modulating their expression could be a promising therapeutic approach. Overexpressing PTEN inhibited cell migration, cell-cycle progression, and promoted apoptosis in prostate cancer cells. Treatment with recombinant adeno-associated virus carrying PTEN or CDKN1B also inhibited tumor growth in mice models.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2022)
Article
Oncology
Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P. Lombard, Chengfei Liu, Allen C. Gao
Summary: Treatment resistance is a common challenge in castration-resistant prostate cancer. This study examines the resistance patterns of different therapeutic classes and emphasizes the importance of rational drug sequencing in treatment. The findings reveal distinct cross-resistance characteristics among different resistant cell sublines and provide insights into the underlying mechanisms of resistance.
Review
Pharmacology & Pharmacy
Milad Ashrafizaden, Navid Rabiee, Alan Prem Kumar, Gautam Sethi, Ali Zarrabi, Yuzhuo Wang
Summary: Long noncoding RNAs (lncRNAs) play a role in gene regulation in pancreatic cancer cells, affecting apoptosis, autophagy, proliferation, metastasis, and drug resistance.
DRUG DISCOVERY TODAY
(2022)
Review
Oncology
Milad Ashrafizadeh, Mahshid Deldar Abad Paskeh, Sepideh Mirzaei, Mohammad Hossein Gholami, Ali Zarrabi, Farid Hashemi, Kiavash Hushmandi, Mehrdad Hashemi, Noushin Nabavi, Francesco Crea, Jun Ren, Daniel J. Klionsky, Alan Prem Kumar, Yuzhuo Wang
Summary: This review discusses the role and regulatory mechanisms of autophagy in prostate cancer. Autophagy can impact cancer cell proliferation, survival, and metastasis, as well as the response to therapy. Targeting autophagic genes and utilizing nanotherapeutics show promise in improving patient prognosis.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Correction
Oncology
Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hashemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh, Alan Prem Kumar
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hshemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh, Alan Prem Kumar
Summary: Non-coding RNAs play significant roles in cancer progression by regulating the expression of enhancer of zeste homolog 2 (EZH2). Different types of ncRNAs, including miRNAs, lncRNAs, and CircRNAs, modulate EZH2 expression through various mechanisms, affecting downstream signaling pathways and therapy response. These mechanisms have important implications for cancer research and treatment.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Cell Biology
Nelson K. Y. Wong, Xin Dong, Yen-Yi Lin, Hui Xue, Rebecca Wu, Dong Lin, Colin Collins, Yuzhuo Wang
Summary: Androgen deprivation therapy is the standard treatment for advanced prostate cancer, but most patients eventually relapse. The study of the dormant phase of prostate cancer progression is hindered by limited clinical tissue and preclinical models. This study uses unique patient-derived xenograft models to investigate the immune evasion mechanisms of dormant prostate cancer cells, providing a framework for further research and immune-based therapies.
Review
Oncology
Sepideh Mirzaei, Mahshid Deldar Abad Paskeh, Elena Okina, Mohammad Hossein Gholami, Kiavash Hushmandi, Mehrdad Hashemi, Azuma Kalu, Ali Zarrabi, Noushin Nabavi, Navid Rabiee, Esmaeel Sharifi, Hassan Karimi-Maleh, Milad Ashrafizadeh, Alan Prem Kumar, Yuzhuo Wang
Summary: This review highlights the role of epigenetic alterations in the development of prostate cancer, specifically focusing on lncRNAs. Aberrant expression of lncRNAs in prostate cancer is well-documented, affecting various molecular pathways and regulating tumor progression. Additionally, lncRNAs play a role in radio-resistance, chemo-resistance, and immune evasion of prostate cancer, making them potential targets for therapeutic interventions.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Biotechnology & Applied Microbiology
Milad Ashrafizadeh, Ali Zarrabi, Hassan Karimi-Maleh, Afshin Taheriazam, Sepideh Mirzaei, Mehrdad Hashemi, Kiavash Hushmandi, Pooyan Makvandi, Ehsan Nazarzadeh Zare, Esmaeel Sharifi, Arul Goel, Lingzhi Wang, Jun Ren, Yavuz Nuri Ertas, Alan Prem Kumar, Yuzhuo Wang, Navid Rabiee, Gautam Sethi, Zhaowu Ma
Summary: Nanomedicine has great potential in the treatment of bladder cancer, including improving drug efficacy, regulating gene expression, providing photodynamic and photothermal therapy, remodeling tumor microenvironment and infiltration of immune cells, timely diagnosis, and targeted therapy for bladder cancer.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Jonathan Chou, Emily A. Egusa, Sinan Wang, Michelle L. Badura, Fei Lee, Anil P. Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M. Robinson, Veronica Steri, Jiaoti Huang, Yuzhuo Wang, Eric J. Small, Emily Chan, Bradley A. Stohr, Alan Ashworth, Brant Delafontaine, Sylvie Rottey, Keegan S. Cooke, Nooshin Hashemi Sadraei, Brian Yu, Mark Salvati, Julie M. Bailis, Felix Y. Feng, Robert R. Flavell, Rahul Aggarwal
Summary: The expression of DLL3 in de novo and treatment-emergent small-cell/neuroendocrine (t-SCNC) prostate cancer is associated with reduced survival. A PET agent, [89Zr]-DFO-DLL3-scFv, has been developed to detect DLL3 levels in mouse SCNC models. The DLL3-targeted bispecific T-cell engager (BiTE) immunotherapy, AMG 757 (tarlatamab), exhibits potent and durable antitumor activity in patient-derived xenograft models.
Article
Urology & Nephrology
Mitchell G. Lawrence, Renea A. Taylor, Georgia B. Cuffe, Lisa S. Ang, Ashlee K. Clark, David L. Goode, Laura H. Porter, Clementine Le Magnen, Nora M. Navone, Jack A. Schalken, Yuzhuo Wang, Wytske M. van Weerden, Eva Corey, John T. Isaacs, Peter S. Nelson, Gail P. Risbridger
Summary: This Perspective article discusses patient-derived xenografts (PDXs) of prostate cancer and their utility in basic and preclinical research. The authors emphasize the need for more diverse and accessible PDX models to reflect patient diversity and study emerging treatment strategies and mechanisms of resistance. Collaboration and data sharing can greatly enhance the use of PDXs in prostate cancer research.
NATURE REVIEWS UROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Fan Zhang, Maitree Biswas, Shabnam Massah, Joseph Lee, Shreyas Lingadahalli, Samantha Wong, Christopher Wells, Jane Foo, Nabeel Khan, Helene Morin, Neetu Saxena, Sonia H. Y. Kung, Bei Sun, Ana Karla Parra Nunez, Christophe Sanchez, Novia Chan, Lauren Ung, Umut Berkay Altintas, Jennifer M. Bui, Yuzhuo Wang, Ladan Fazli, Htoo Zarni Oo, Paul S. Rennie, Nathan A. Lack, Artem Cherkasov, Martin E. Gleave, Jorg Gsponer, Nada Lallous
Summary: Numerous cancers, including prostate cancer (PCa), rely on transcription programs driven by specific genomic regions called super-enhancers. The androgen receptor (AR), the main oncogenic driver in PCa, forms liquid-like foci in different PCa models, and this foci formation is correlated with AR transcriptional activity. AR antagonists inhibit foci formation and phase separation of AR, suggesting that enhanced compartmentalization of AR and coactivators may play a crucial role in the activation of oncogenic transcription programs in androgen-dependent PCa.
NUCLEIC ACIDS RESEARCH
(2023)
Article
Oncology
Jamie M. Sperger, Kyle T. Helzer, Charlotte N. Stahlfeld, Dawei Jiang, Anupama Singh, Katherine R. Kaufmann, David J. Niles, Erika Heninger, Nicholas R. Rydzewski, Liguo Wang, Liewei Wang, Rendong Yang, Yanan Ren, Jonathan W. Engle, Peng Huang, Christos E. Kyriakopoulos, Susan F. Slovin, Howard R. Soule, Shuang G. Zhao, Manish Kohli, Scott T. Tagawa, Weibo Cai, Scott M. Dehm, Joshua M. Lang
Summary: This study analyzed the expression of biomarkers in prostate cancer patients and demonstrated that TROP-2 can serve as a cell surface target for isolating circulating tumor cells, and it may serve as a predictive biomarker for antibody-drug conjugates.
CLINICAL CANCER RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Reyadh R. Al-Rashidi, Sara Abdalrazzaq M. Noraldeen, Ali Kamil Kareem, Aisha Kamal Mahmoud, Wesam R. Kadhum, Andres Alexis Ramirez-Coronel, Acim Heri Iswanto, Rasha Fadhel Obaid, Abduladheem Turki Jalil, Yasser Fakri Mustafa, Noushin Nabavi, Yuzhuo Wang, Lin Wang
Summary: Prostate carcinoma is a malignant disease caused by genomic alterations in the prostate. Dysregulation of NF-kappa B pathway promotes carcinogenesis and resistance to therapy. Research on genetic mutations and NF-kappa B function has the potential to introduce novel therapies for this incurable disease. Noncoding RNA transcripts can regulate NF-kappa B level, offering a potential avenue for modulating prostate cancer progression.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Oncology
Rui Sun, Binyuan Yan, Hao Li, Donglin Ding, Liguo Wang, Jun Pang, Dingwei Ye, Haojie Huang
Summary: Upregulation of SLC7A11 by androgen receptor variants inhibits antiandrogen-induced prostate cancer cell ferroptosis and contributes to castration resistance in prostate cancer.
Article
Multidisciplinary Sciences
Donglin Ding, Alexandra M. Blee, Jianong Zhang, Yunqian Pan, Nicole A. Becker, L. James Maher, Rafael Jimenez, Liguo Wang, Haojie Huang
Summary: This study demonstrates that TP53 gene alteration and TMPRSS2-ERG fusion act together to promote prostate cancer development. Gain-of-function mutant p53 is shown to bind to a specific DNA sequence in the CTNNB1 gene promoter and activate its expression. ERG and β-Catenin co-occupy sites at pyrimidine synthesis gene loci and promote pyrimidine synthesis and prostate cancer growth. Inhibition of β-Catenin suppresses the growth of TMPRSS2-ERG and p53 mutant-positive prostate cancer cells in vitro and in mice.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, Research & Experimental
Mu-En Wang, Jiaqi Chen, Yi Lu, Alyssa R. Bawcom, Jinjin Wu, Jianhong Ou, John M. Asara, Andrew J. Armstrong, Qianben Wang, Lei Li, Yuzhuo Wang, Jiaoti Huang, Ming Chen
Summary: Inactivation of the RB1 tumor suppressor gene is common in therapy-resistant cancers and predicts poor clinical outcomes. Loss of RB1 and activation of E2F sensitizes cancer cells to ferroptosis, and targeting this pathway with a GPX4 inhibitor inhibits tumor growth and improves survival in RB1-deficient cancers. These findings suggest a promising therapeutic approach for RB1-deficient malignancies.
JOURNAL OF CLINICAL INVESTIGATION
(2023)